<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by José @ Vidal on Medium]]></title>
        <description><![CDATA[Stories by José @ Vidal on Medium]]></description>
        <link>https://medium.com/@joseavidal?source=rss-cbfb0461405b------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*6iJlnMUnlgunScjE9TJhxw@2x.jpeg</url>
            <title>Stories by José @ Vidal on Medium</title>
            <link>https://medium.com/@joseavidal?source=rss-cbfb0461405b------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Sun, 22 Nov 2026 07:12:15 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@joseavidal/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Critical Thinking (VI): The Hour of Technocrats and the Opportunity Cost of Governance]]></title>
            <description><![CDATA[<div class="medium-feed-item"><p class="medium-feed-image"><a href="https://medium.com/jose-a-vidal/critical-thinking-vi-the-hour-of-technocrats-and-the-opportunity-cost-of-governance-c249092926d3?source=rss-cbfb0461405b------2"><img src="https://cdn-images-1.medium.com/max/1024/1*1_vxQ5WH3enckex9p1ixXw.jpeg" width="1024"></a></p><p class="medium-feed-snippet">The month is coming to an end, and it is time for me to write, but this is a difficult post for this online portfolio where I have been&#x2026;</p><p class="medium-feed-link"><a href="https://medium.com/jose-a-vidal/critical-thinking-vi-the-hour-of-technocrats-and-the-opportunity-cost-of-governance-c249092926d3?source=rss-cbfb0461405b------2">Continue reading on Jose @ Vidal »</a></p></div>]]></description>
            <link>https://medium.com/jose-a-vidal/critical-thinking-vi-the-hour-of-technocrats-and-the-opportunity-cost-of-governance-c249092926d3?source=rss-cbfb0461405b------2</link>
            <guid isPermaLink="false">https://medium.com/p/c249092926d3</guid>
            <category><![CDATA[data-governance]]></category>
            <category><![CDATA[infrastructure-as-code]]></category>
            <category><![CDATA[critical-infrastructure]]></category>
            <category><![CDATA[critical-thinking]]></category>
            <category><![CDATA[technocracy]]></category>
            <dc:creator><![CDATA[José @ Vidal]]></dc:creator>
            <pubDate>Sat, 31 Oct 2026 20:34:33 GMT</pubDate>
            <atom:updated>2026-11-05T14:06:50.658Z</atom:updated>
        </item>
        <item>
            <title><![CDATA[Critical Thinking (V): Lack of Interoperability, a Governance Problem]]></title>
            <description><![CDATA[<div class="medium-feed-item"><p class="medium-feed-image"><a href="https://medium.com/jose-a-vidal/in-july-of-this-year-the-oecd-published-a-new-report-oecd-health-working-papers-197-0e9322d9e693?source=rss-cbfb0461405b------2"><img src="https://cdn-images-1.medium.com/max/900/1*2Ny54rLjLuVqXpg6kDSaNw.png" width="900"></a></p><p class="medium-feed-snippet">In July of this year, the OECD published a new report- OECD Health Working Papers &#x2116;197: Interoperability in healthcare- based on 41&#x2026;</p><p class="medium-feed-link"><a href="https://medium.com/jose-a-vidal/in-july-of-this-year-the-oecd-published-a-new-report-oecd-health-working-papers-197-0e9322d9e693?source=rss-cbfb0461405b------2">Continue reading on Jose @ Vidal »</a></p></div>]]></description>
            <link>https://medium.com/jose-a-vidal/in-july-of-this-year-the-oecd-published-a-new-report-oecd-health-working-papers-197-0e9322d9e693?source=rss-cbfb0461405b------2</link>
            <guid isPermaLink="false">https://medium.com/p/0e9322d9e693</guid>
            <category><![CDATA[politics]]></category>
            <category><![CDATA[data-science]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[big-data]]></category>
            <category><![CDATA[technology]]></category>
            <dc:creator><![CDATA[José @ Vidal]]></dc:creator>
            <pubDate>Wed, 30 Sep 2026 19:43:29 GMT</pubDate>
            <atom:updated>2026-10-01T07:45:47.572Z</atom:updated>
        </item>
        <item>
            <title><![CDATA[RNA as the Programmable Language of Medicine]]></title>
            <description><![CDATA[<div class="medium-feed-item"><p class="medium-feed-image"><a href="https://medium.com/jose-a-vidal/rna-as-the-programmable-language-of-medicine-4733a762e44d?source=rss-cbfb0461405b------2"><img src="https://cdn-images-1.medium.com/max/1536/1*okbHK_Pb8unZ9N8resd6Tg.png" width="1536"></a></p><p class="medium-feed-snippet">Just a few days ago, a piece of news once again placed three letters at the heart of one of the most fascinating scientific stories of our&#x2026;</p><p class="medium-feed-link"><a href="https://medium.com/jose-a-vidal/rna-as-the-programmable-language-of-medicine-4733a762e44d?source=rss-cbfb0461405b------2">Continue reading on Jose @ Vidal »</a></p></div>]]></description>
            <link>https://medium.com/jose-a-vidal/rna-as-the-programmable-language-of-medicine-4733a762e44d?source=rss-cbfb0461405b------2</link>
            <guid isPermaLink="false">https://medium.com/p/4733a762e44d</guid>
            <category><![CDATA[data-science]]></category>
            <category><![CDATA[science]]></category>
            <category><![CDATA[programming]]></category>
            <category><![CDATA[technology]]></category>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[José @ Vidal]]></dc:creator>
            <pubDate>Mon, 31 Aug 2026 11:40:05 GMT</pubDate>
            <atom:updated>2026-08-31T11:40:48.451Z</atom:updated>
        </item>
        <item>
            <title><![CDATA[From Fitbit to Google Health: an X-ray of an integration]]></title>
            <description><![CDATA[<div class="medium-feed-item"><p class="medium-feed-image"><a href="https://medium.com/jose-a-vidal/from-fitbit-to-google-an-x-ray-of-an-integration-f9af7cb509b7?source=rss-cbfb0461405b------2"><img src="https://cdn-images-1.medium.com/max/1024/1*HpE65ktLZcnczpBLS5tYqA.jpeg" width="1024"></a></p><p class="medium-feed-snippet">In 2014, we included Fitbit in our Sportstech project. Although the project ultimately fell through due to the pandemic and several&#x2026;</p><p class="medium-feed-link"><a href="https://medium.com/jose-a-vidal/from-fitbit-to-google-an-x-ray-of-an-integration-f9af7cb509b7?source=rss-cbfb0461405b------2">Continue reading on Jose @ Vidal »</a></p></div>]]></description>
            <link>https://medium.com/jose-a-vidal/from-fitbit-to-google-an-x-ray-of-an-integration-f9af7cb509b7?source=rss-cbfb0461405b------2</link>
            <guid isPermaLink="false">https://medium.com/p/f9af7cb509b7</guid>
            <category><![CDATA[technology]]></category>
            <category><![CDATA[data-science]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[ai]]></category>
            <category><![CDATA[google]]></category>
            <dc:creator><![CDATA[José @ Vidal]]></dc:creator>
            <pubDate>Thu, 30 Jul 2026 23:25:49 GMT</pubDate>
            <atom:updated>2026-08-04T07:58:45.042Z</atom:updated>
        </item>
        <item>
            <title><![CDATA[Critical Thinking (IV): Spanish Health Policy, A Downpour of Regulations and Laws]]></title>
            <description><![CDATA[<div class="medium-feed-item"><p class="medium-feed-image"><a href="https://medium.com/jose-a-vidal/critical-thinking-iv-spanish-health-policy-a-downpour-of-regulations-and-laws-d5338f1a8eb8?source=rss-cbfb0461405b------2"><img src="https://cdn-images-1.medium.com/max/1536/1*0rNqvm052xm0wwP0xfIQXg.png" width="1536"></a></p><p class="medium-feed-snippet">In recent months, the Spanish Ministry of Health has launched one of the most ambitious regulatory agendas in recent years.</p><p class="medium-feed-link"><a href="https://medium.com/jose-a-vidal/critical-thinking-iv-spanish-health-policy-a-downpour-of-regulations-and-laws-d5338f1a8eb8?source=rss-cbfb0461405b------2">Continue reading on Jose @ Vidal »</a></p></div>]]></description>
            <link>https://medium.com/jose-a-vidal/critical-thinking-iv-spanish-health-policy-a-downpour-of-regulations-and-laws-d5338f1a8eb8?source=rss-cbfb0461405b------2</link>
            <guid isPermaLink="false">https://medium.com/p/d5338f1a8eb8</guid>
            <category><![CDATA[law]]></category>
            <category><![CDATA[policy]]></category>
            <category><![CDATA[regulation]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[spain]]></category>
            <dc:creator><![CDATA[José @ Vidal]]></dc:creator>
            <pubDate>Sun, 28 Jun 2026 22:21:28 GMT</pubDate>
            <atom:updated>2026-06-30T06:34:52.473Z</atom:updated>
        </item>
        <item>
            <title><![CDATA[Varda Space Industries and United Therapeutics: When Low Earth Orbit Starts Looking Like a Supply…]]></title>
            <description><![CDATA[<div class="medium-feed-item"><p class="medium-feed-image"><a href="https://medium.com/jose-a-vidal/varda-space-industries-and-united-therapeutics-when-low-earth-orbit-starts-looking-like-a-supply-73790b485a51?source=rss-cbfb0461405b------2"><img src="https://cdn-images-1.medium.com/max/1536/1*ifzdjpI6qyfx-F3Xxhd2Aw.png" width="1536"></a></p><p class="medium-feed-snippet">This is not the first time we have exposed Varda Space Industries in this online portfolio. The first publication dates back to mid-2023&#x2026;</p><p class="medium-feed-link"><a href="https://medium.com/jose-a-vidal/varda-space-industries-and-united-therapeutics-when-low-earth-orbit-starts-looking-like-a-supply-73790b485a51?source=rss-cbfb0461405b------2">Continue reading on Jose @ Vidal »</a></p></div>]]></description>
            <link>https://medium.com/jose-a-vidal/varda-space-industries-and-united-therapeutics-when-low-earth-orbit-starts-looking-like-a-supply-73790b485a51?source=rss-cbfb0461405b------2</link>
            <guid isPermaLink="false">https://medium.com/p/73790b485a51</guid>
            <category><![CDATA[space-exploration]]></category>
            <category><![CDATA[microgravity]]></category>
            <category><![CDATA[microgravity-research]]></category>
            <category><![CDATA[drugs]]></category>
            <category><![CDATA[space]]></category>
            <dc:creator><![CDATA[José @ Vidal]]></dc:creator>
            <pubDate>Thu, 28 May 2026 12:26:25 GMT</pubDate>
            <atom:updated>2026-05-28T18:02:40.756Z</atom:updated>
        </item>
        <item>
            <title><![CDATA[The Multiplier Effect of Compound Interest in Health (II)]]></title>
            <description><![CDATA[<div class="medium-feed-item"><p class="medium-feed-image"><a href="https://medium.com/jose-a-vidal/the-multiplier-effect-of-compound-interest-in-health-ii-77ee3cf53702?source=rss-cbfb0461405b------2"><img src="https://cdn-images-1.medium.com/max/1536/1*fbKngZlkUCcXORG3HcUB0A.png" width="1536"></a></p><p class="medium-feed-snippet">In October 2024, I wrote in this online portfolio about how compound interest not only transforms financial capital, but also our health&#x2026;</p><p class="medium-feed-link"><a href="https://medium.com/jose-a-vidal/the-multiplier-effect-of-compound-interest-in-health-ii-77ee3cf53702?source=rss-cbfb0461405b------2">Continue reading on Jose @ Vidal »</a></p></div>]]></description>
            <link>https://medium.com/jose-a-vidal/the-multiplier-effect-of-compound-interest-in-health-ii-77ee3cf53702?source=rss-cbfb0461405b------2</link>
            <guid isPermaLink="false">https://medium.com/p/77ee3cf53702</guid>
            <category><![CDATA[compound-interest]]></category>
            <category><![CDATA[prevention]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[ai]]></category>
            <category><![CDATA[economics]]></category>
            <dc:creator><![CDATA[José @ Vidal]]></dc:creator>
            <pubDate>Wed, 29 Apr 2026 23:06:28 GMT</pubDate>
            <atom:updated>2026-05-04T06:55:02.216Z</atom:updated>
        </item>
        <item>
            <title><![CDATA[As for the results of the AMIE feasibility study]]></title>
            <description><![CDATA[<div class="medium-feed-item"><p class="medium-feed-image"><a href="https://medium.com/jose-a-vidal/on-the-results-of-the-amie-feasibility-study-d991ce58d0c9?source=rss-cbfb0461405b------2"><img src="https://cdn-images-1.medium.com/max/1479/1*1zdADnOzc6e4cm8zzy7vxQ.png" width="1479"></a></p><p class="medium-feed-snippet">In my monthly publication in April 2025, I have already devoted a few lines to analyze the research conducted by Google for Health in this&#x2026;</p><p class="medium-feed-link"><a href="https://medium.com/jose-a-vidal/on-the-results-of-the-amie-feasibility-study-d991ce58d0c9?source=rss-cbfb0461405b------2">Continue reading on Jose @ Vidal »</a></p></div>]]></description>
            <link>https://medium.com/jose-a-vidal/on-the-results-of-the-amie-feasibility-study-d991ce58d0c9?source=rss-cbfb0461405b------2</link>
            <guid isPermaLink="false">https://medium.com/p/d991ce58d0c9</guid>
            <category><![CDATA[digital-transformation]]></category>
            <category><![CDATA[ai]]></category>
            <category><![CDATA[google]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[healthcare]]></category>
            <dc:creator><![CDATA[José @ Vidal]]></dc:creator>
            <pubDate>Tue, 31 Mar 2026 07:22:34 GMT</pubDate>
            <atom:updated>2026-03-31T11:42:13.867Z</atom:updated>
        </item>
        <item>
            <title><![CDATA[Price pressure and the minimum viable organization]]></title>
            <link>https://medium.com/jose-a-vidal/price-pressure-and-the-minimum-viable-organization-a595f1d81225?source=rss-cbfb0461405b------2</link>
            <guid isPermaLink="false">https://medium.com/p/a595f1d81225</guid>
            <category><![CDATA[future-of-work]]></category>
            <category><![CDATA[technology]]></category>
            <category><![CDATA[politics]]></category>
            <category><![CDATA[biotech]]></category>
            <category><![CDATA[healthcare]]></category>
            <dc:creator><![CDATA[José @ Vidal]]></dc:creator>
            <pubDate>Sat, 28 Feb 2026 20:43:37 GMT</pubDate>
            <atom:updated>2026-03-02T20:50:58.686Z</atom:updated>
            <content:encoded><![CDATA[<p>Everything that happens in the United States eventually reaches Europe, even if it´s with some delay- an old continent in every sense.<br> In recent weeks, two very clear signals have emerged:</p><ol><li>The launch from the White House of <a href="https://trumprx.gov/">TrumpRx.</a></li><li>The organizational shift driven by <strong>Jack Dorsey at Block Inc.</strong></li></ol><p><a href="https://trumprx.gov/">TrumpRx</a> represents an attempt to introduce a more transparent market mechanism into drug pricing in the United States, one of the highest-priced markets in the world. The economic logic is clear: if prices are compared more directly with European ones, or if access is digitized through platforms, companies lose part of their historical ability to segment markets and maximize revenue.</p><p>These kinds of initiatives affect not only revenues but also the internal structure of companies. For decades, large pharmaceutical firms have maintained extensive commercial and administrative organizations adapted to the regulatory specificities of each country, or even each insurer. If price becomes a more transparent and comparable variable, that model loses economic justification.</p><p>Various health policy analyses published by institutions such as RAND Health Care and Health Affairs have pointed out that price transparency tends to compress margins and encourage reductions in structural costs. In this context, <a href="https://trumprx.gov/">TrumpRx </a>can be interpreted as a catalyst accelerating an already existing trend: <strong>the need to operate with more adaptable structures. Jobs do not disappear, but their nature changes.</strong></p><p>For example, <a href="https://x.com/jack/status/2027129697092731343?s=20">Jack Dorsey’s most recent move at Block</a> is particularly relevant because it shows how a modern company responds to pressure for structural efficiency. The company announced a reorganization centered on artificial intelligence and automation, <strong>with the explicit goal of operating with smaller teams and greater individual productivity.</strong></p><p>This approach is not based solely on reducing salary costs, but on eliminating what business economics calls <strong>“organizational sunk costs”:</strong> structures that exist because they have always existed, not because they are still necessary. Oversized offices, layers of middle management, and redundant departments are typical examples of this phenomenon.</p><p><strong>The model emerging in the technology sector is that of the minimum viable organization: </strong>small, highly qualified teams supported by advanced digital tools. According to various analyses in Forbes and MIT Technology Review, artificial intelligence makes it possible to automate tasks that previously required entire teams, from customer support to basic programming and data analysis.</p><p>This shift has direct implications for the life sciences. Although pharma and biotech are more regulated and experimental industries than software.</p><p>Both industries share many administrative and analytical functions that can be automated.</p><p><strong>The key lesson from the Block case is not technological but organizational:</strong> when technology increases individual productivity, companies tend to reduce in size in order to gain agility.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*dRo2Cb_f6TMNrxd4T5vGBQ.png" /><figcaption>Source: Pic generated by Chat GPT5.</figcaption></figure><p>If we add to these two developments in the United States <a href="https://medium.com/jose-a-vidal/a-few-weeks-ago-mia-malmenas-and-xin-zhao-published-in-health-economics-a-rather-simple-and-09cfd8e8ba6d">the Joint Clinical Assessment (JCA) process — formally launched with the European regulation on health technology assessment that began to be implemented in 2025 — we see a structural change in the way medicines are evaluated in Europe.</a></p><p>Traditionally, each country carried out its own clinical assessments, forcing companies to maintain parallel teams to interact with each national agency. The JCA introduces joint clinical evaluations at the European level, reducing duplication of effort.</p><p>The European Commission has indicated that the goal of the system is to <strong>improve efficiency and accelerate access</strong> to innovative medicines. But from a business perspective, the most important impact is organizational: <strong>fewer parallel evaluations mean less need for full national structures.</strong></p><p>Consulting firms such as IQVIA and Deloitte have warned that the JCA will require companies to redesign their clinical evidence generation processes, integrating European comparative requirements from the outset. <strong>This favors smaller cross-functional teams over isolated national departments.</strong></p><p>In other words, <strong>the JCA pushes pharma toward the same kind of lean organization already seen in technology.</strong></p><p>If we combine TrumpRx, the example of Block’s new organizational model, and the European JCA process, a clear direction emerges for the next 25 years: the transition from capital-intensive structures toward more flexible models based on operating expenditure.</p><p>Traditional CAPEX in pharma included large corporate headquarters, extensive in-house laboratories, and oversized permanent structures designed to absorb uncertainty. <strong>In the future, many of these functions will be outsourced or converted into on-demand services.</strong></p><p>OPEX, by contrast, allows resources to be adjusted dynamically. Clinical trials managed by CROs, cloud computing infrastructure, and distributed teams are examples of this approach.</p><p>This shift will have several labor consequences:</p><ul><li>Less permanent employment and more project-based work.</li><li>Greater demand for hybrid profiles capable of integrating science, data, and regulation.</li><li>Less importance of the physical location of work.</li></ul><p><strong>Companies will seek to minimize sunk costs because these reduce their ability to adapt. In an environment where prices are more regulated and clinical evidence more standardized, competitive advantage will increasingly depend on adaptability and flexibility.</strong></p><p>In 25 years, many pharmaceutical companies will likely resemble coordinated networks more than traditional corporations. They will retain key competencies internally while outsourcing many of their operations.</p><p>The result will not necessarily be less innovation, but <strong>a different type of organization: lighter, more distributed, and more dependent on technological capabilities.</strong> In that sense, the current transformation can be understood as part of a broader transition towards an economy in which <strong>size ceases to be a structural advantage and adaptability becomes the primary asset.</strong></p><p><a href="https://joseavidal.com/la-presion-en-los-precios-y-la-organizacion-minima-viable/">ES version</a></p><p>EDUCATIONAL PILLS:</p><p>International Master in Medical Affairs. Program offered by the BioTech and Pharma School. In Memoriam César Nombela. Certified by the Catholic University of Ávila.<a href="https://www.imf-formacion.com/masters-profesionales/master-medical-affairs"> Information.</a><br>Advanced Management Program. IE Business School. Executive Development Programs. <a href="https://landings.ie.edu/xlland-xl-es-advanced-management-program?utm_source=adwords&amp;utm_medium=ppc&amp;utm_campaign=CAMP+-+EXE+-+AMP+-+AMP-REG+-+ESP+-+ES+-+SEM+-+BRA&amp;utm_term=ie+amp&amp;hsa_acc=5632523758&amp;hsa_cam=10321854673&amp;hsa_grp=105321203200&amp;hsa_ad=442898521325&amp;hsa_src=g&amp;hsa_tgt=kwd-363784343422&amp;hsa_kw=ie+amp&amp;hsa_mt=e&amp;hsa_net=adwords&amp;hsa_ver=3&amp;gclid=Cj0KCQjw8eOLBhC1ARIsAOzx5cHnCMoNGAsM2fdiJiWP-adzemjdqbztdu-7dm3nzSN8r_OovFbbPIQaAlbnEALw_wcB">Information.</a></p><p>READING PILLS:</p><p>White House’s TrumpRx platform has arrived. <a href="https://pharmaphorum.com/news/white-houses-trumprx-platform-has-arrived">Pharmaphorum</a></p><p>A multimodal sleep foundation model for disease prediction. Rahul Thapa, Magnus Ruud Kjaer, Bryan He, Ian Covert, Hyatt Moore IV, Umaer Hanif, Gauri Ganjoo, M. Brandon Westover, Poul Jennum, Andreas Brink-Kjaer, Emmanuel Mignot &amp; James Zou. <a href="https://www.nature.com/articles/s41591-025-04133-4?utm_source=signals.superpower.com&amp;utm_medium=newsletter&amp;utm_campaign=130-diseases-hiding-in-your-sleep&amp;_bhlid=42191373b33c1b91704adba14ebb374f72d27b65">Nature Medicine</a></p><p>Associations of Slow-Wave Sleep With Prevalent and Incident Type 2 Diabetes in the Multi-Ethnic Study of Atherosclerosis <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10686689/">NIH</a></p><p>Impact of Sleep Disorders and Disturbed Sleep on Brain Health: A Scientific Statement From the American Heart Association <a href="https://www.ahajournals.org/doi/10.1161/STR.0000000000000453?utm_source=chatgpt.com">AHA/ASA Journal</a></p><p>Association of sleep duration with risk of all-cause mortality and poor quality of dying in oldest-old people: a community-based longitudinal study <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7507281/">NIH</a></p><p>Association Between Slow-Wave Sleep Loss and Incident Dementia <a href="https://jamanetwork.com/journals/jamaneurology/fullarticle/2810957">JAMA Neurology</a></p><p>Age estimation from sleep studies using deep learning predicts life expectancy <a href="https://www.nature.com/articles/s41746-022-00630-9">NPJ Digital Medicine</a></p><p>Five Unconquered Frontiers for Longevity biotech: Our 2026 Call for Proposals. <a href="https://www.librariesforthefuture.bio/p/five-unconquered-frontiers-for-longevity?utm_source=post-email-title&amp;publication_id=1898564&amp;post_id=187871176&amp;utm_campaign=email-post-title&amp;isFreemail=true&amp;r=7p3kg&amp;triedRedirect=true&amp;utm_medium=email">Libraries for the future</a></p><p>Exclusive: In major test for longevity field, FDA greenlights study on a ‘near total reset’ of cells <a href="https://endpoints.news/exclusive-fda-greenlights-gene-therapy-study-to-rewind-the-age-of-cells/">END POINTS</a></p><p>Triple cardiovascular disease detection with an artificial intelligence-enabled stethoscope (TRICORDER) in the UK: a cluster-randomised controlled implementation trial. Mihir A Kelshiker, PhDa,c,† ∙ Patrik Bächtiger, PhDa,c,† ∙ Camille F Petri, MDa ∙ Saloni Nakhare, MBBSa ∙ Josephine Mansell, MBBSa ∙ Karanjot Chhatwal, BSca. <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02156-7/fulltext?utm_source=The+Medical+Futurist+Newsletter&amp;utm_campaign=9ebbef8697-EMAIL_CAMPAIGN_2022_02_01_COPY_01&amp;utm_medium=email&amp;utm_term=0_efd6a3cd08-9ebbef8697-%5bLIST_EMAIL_ID%5d&amp;mc_cid=9ebbef8697&amp;mc_eid=00409a11e1">The Lancet</a></p><p>STARTUP PILLS:</p><p><a href="https://capitalcell.com/en/explore/">Investment opportunities. </a>Capital Cell.</p><p>The $3B Preventive Health Race. Ivan Landabaso. <a href="https://www.startupriders.com/p/preventive-health-startups-function-neko-prenuvo?utm_source=post-email-title&amp;publication_id=63213&amp;post_id=181784822&amp;utm_campaign=email-post-title&amp;isFreemail=true&amp;r=7p3kg&amp;triedRedirect=true&amp;utm_medium=email">Startup Riders</a></p><p>EVENT PILLS:</p><p>World EPA Congress. Amsterdam. March 3- 4, 2026. <a href="https://www.terrapinn.com/conference/pharma-pricing/index.stm?utm_source=partners&amp;utm_medium=healtheconomics&amp;utm_campaign=part&amp;trc=part">Registration</a></p><p>ISPOR. May 1- 20, 2026. <a href="https://www.ispor.org/conferences-education/conferences/upcoming-conferences/ispor-2026/program/program/?utm_medium=email&amp;utm_source=database&amp;utm_campaign=ispor_2026&amp;utm_content=register_ispor-2026_program-live_feb9&amp;mkt_tok=NjM4LVBYUi0zMTgAAAGf4tuLkaNRViUsiXpB1pzCpFg_4CDHUKBqvyAFvf2dC6Wp5Wf4N3HmykyfieV02xGYVURcsMDa_2uCUFRESJ63Hn94v6SKSQJBZKqOi9M">Registration</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a595f1d81225" width="1" height="1" alt=""><hr><p><a href="https://medium.com/jose-a-vidal/price-pressure-and-the-minimum-viable-organization-a595f1d81225">Price pressure and the minimum viable organization</a> was originally published in <a href="https://medium.com/jose-a-vidal">Jose @ Vidal</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The lessons of Katy]]></title>
            <link>https://medium.com/jose-a-vidal/the-lessons-of-katy-bc1ddf8c2df6?source=rss-cbfb0461405b------2</link>
            <guid isPermaLink="false">https://medium.com/p/bc1ddf8c2df6</guid>
            <category><![CDATA[pets]]></category>
            <category><![CDATA[physical-health]]></category>
            <category><![CDATA[dogs]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[mental-health]]></category>
            <dc:creator><![CDATA[José @ Vidal]]></dc:creator>
            <pubDate>Sat, 31 Jan 2026 18:00:42 GMT</pubDate>
            <atom:updated>2026-02-02T07:27:59.711Z</atom:updated>
            <content:encoded><![CDATA[<p>This first post of 2026 may be one of the least professional I’ve published since I started sharing content back in 2013.</p><p>I’m not the best person to talk about pets, and dogs in particular, but in any case, I think Katy deserves a special mention.</p><p>She was born in August 2017 and a few weeks later we welcomed a beautiful Irish Setter puppy into our home. I’ll try to explain it by emulating the great Toni Simón:</p><blockquote>An Irish Setter puppy, golden-brown in colour, is pure poetry in motion: curious eyes, a noble gaze, and a warm glow that seems to be captured from the sun itself. Its silky coat falls like a gentle caress, somewhere between copper and honey, announcing elegance even before it grows. It has the overflowing tenderness of one who is discovering the world, and the calm dignity of a breed with an ancient soul. It is a living beauty, yes, but also a promise of loyalty, energy, and unconditional joy.</blockquote><p>Well then, this January, on an ordinary Saturday, Katy had some retching, and foolishly, I thought it was simply because, by gnawing and tearing at her mattress, she had swallowed some hairballs and that, once she managed to vomit them up, she would be able to rest peacefully in the living room.</p><p>That was exactly what happened: two significant bouts of vomiting and then a calm, deep rest — so deep that it allowed me to keep watching the second half of a ridiculous football match, the second half of a Las Palmas–Dépor.</p><p>As soon as Eva came into the house, in a broken voice she warned me that Katy had her eyes open and wasn’t breathing. She was probably already dead, but with the help of Luis, a good neighbour who acts as a grandfather and even more, we lifted her into the car to take her quickly to the vet, where, as soon as we arrived, they confirmed her death.</p><p>I can’t describe the family’s grief and tears, or Luis’s… but in my case, I didn’t shed a single tear. A mix of disbelief and guilt overwhelmed me: how is it possible that an apparently healthy dog, with a healthy -almost too healthy- appearance, could die within a few hours right in front of me without my being able to realize what was happening?</p><p>At the vet Hospital, they explained that she had died from <strong>gastric torsion</strong>. It is a severe and often fatal veterinary emergency in which the stomach dilates and twists, trapping gases and fluids. That twisting cuts off the blood supply and causes intense pain, rapid shock, and a risk of death within a few hours. It mainly affects large, deep-chested dogs and requires immediate surgery. In fact, the vet on duty tried to ease my sense of guilt by saying that even if I had rushed Katy to the vet, it was more than likely that she would have died on the operating table.</p><p>In Luis´s case (83), I have a good example of the positive effect that having a dog as a pet has on health. In fact, there are various publications on the subject: it is associated with significant <a href="https://www.akc.org/expert-advice/news/studies-show-owning-dog-connected-to-living-longer/?utm_source=chatgpt.com">reductions in the risk of death after a heart attack or stroke</a> compared to not having a dog; it is also linked to <a href="https://pubmed.ncbi.nlm.nih.gov/36915903/">better physical and cognitive function in older age</a>, which can contribute to healthier aging, as well as <a href="https://pubmed.ncbi.nlm.nih.gov/36915903/">reducing sedentary behavior</a> in owners.</p><p>Even today, it’s hard for me to accept that Katy is no longer here… she left far too young, at just eight and a half years old, but she left teaching us lessons until the very end. She left without disturbing anyone, suffering in silence until her last breath, on her mattress in the living room.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/960/1*eYDyplzISAi5q2rvZpPv2g.jpeg" /><figcaption>Katy (2017–2026). RIP</figcaption></figure><p>Katy is gone, but many lessons remain: The lessons of Katy.</p><p><a href="https://joseavidal.com/las-lecciones-de-katy/">ES version</a></p><p>EDUCATIONAL PILLS:</p><p>International Master in Medical Affairs. Program offered by the BioTech and Pharma School. In Memoriam César Nombela. Certified by the Catholic University of Ávila.<a href="https://www.imf-formacion.com/masters-profesionales/master-medical-affairs"> Information.</a><br>Advanced Management Program. IE Business School. Executive Development Programs. <a href="https://landings.ie.edu/xlland-xl-es-advanced-management-program?utm_source=adwords&amp;utm_medium=ppc&amp;utm_campaign=CAMP+-+EXE+-+AMP+-+AMP-REG+-+ESP+-+ES+-+SEM+-+BRA&amp;utm_term=ie+amp&amp;hsa_acc=5632523758&amp;hsa_cam=10321854673&amp;hsa_grp=105321203200&amp;hsa_ad=442898521325&amp;hsa_src=g&amp;hsa_tgt=kwd-363784343422&amp;hsa_kw=ie+amp&amp;hsa_mt=e&amp;hsa_net=adwords&amp;hsa_ver=3&amp;gclid=Cj0KCQjw8eOLBhC1ARIsAOzx5cHnCMoNGAsM2fdiJiWP-adzemjdqbztdu-7dm3nzSN8r_OovFbbPIQaAlbnEALw_wcB">Information.</a></p><p>READING PILLS:</p><p>Guiding principles of good AI practice in drug development. January 2026. <a href="https://www.ema.europa.eu/en/documents/other/guiding-principles-good-ai-practice-drug-development_en.pdf">FDA + EMA.</a></p><p>Adenocarcinoma ductal de páncreas. January 2026. <a href="https://criscancer.org/adenocarcinoma-ductal-de-pancreas">Fundación Cris contra el Cáncer.</a></p><p>What if AI competed on healthcare outcomes? January 2026. <a href="https://nelsonadvisors.co.uk/blog/what-if-ai-competed-on-healthcare-outcomes">Nelson Advisors.</a></p><p>AI is ending the golden age of strategy consulting: just ask McKinsey. <a href="https://medium.com/enrique-dans/ai-is-ending-the-golden-age-of-strategy-consulting-just-ask-mckinsey-c42261555b16">Enrique Dans.</a></p><p>ChatGPT Health: personalization, power and the price of our medical data. <a href="https://medium.com/enrique-dans/chatgpt-health-personalization-power-and-the-price-of-our-medical-data-0ee525c53db5">Enrique Dans.</a></p><p>STARTUP PILLS:</p><p><a href="https://capitalcell.com/en/explore/">Investment opportunities. </a>Capital Cell.</p><p>PODCAST PILLS:</p><p>Editors’ Choice: Top Stories of 2025. December 2025. <a href="https://www.genengnews.com/topics/genome-editing/editors-choice-top-stories-of-2025/?utm_campaign=GEN%20Daily%20Newsletter&amp;utm_medium=email&amp;_hsenc=p2ANqtz-9mVuxeNLu8xcaZ1IXsr0VF_VzhyGdA7jh3MTD2wPjkI72e_lvYnU7jtHnqwRrlS_5o5KsGunPt1Aky-XjdYlPC7kx8NQUnILWPIfz7iHljriTbEVw&amp;_hsmi=395766927&amp;utm_content=395766927&amp;utm_source=hs_email">Genetic Engineering &amp; Biology News.</a></p><p>EVENT PILLS:</p><p>How Cost-Effective is AI in Healthcare? CelforPharma. Feb, 11–2026 <a href="https://www.celforpharma.com/tips-and-insights/how-cost-effective-ai-healthcare?utm_source=C.E.L.forPharma&amp;utm_medium=email&amp;utm_term=&amp;utm_content=WBINAR&amp;utm_campaign=HECHOLHTA">Registration</a></p><p>Workshop on Economics of Ageing. Call for papers. AESalud, April, 26–2026. <a href="https://www.ub.edu/oap/activitats/workshop-on-economics-of-ageing/">Link to send papers.</a></p><p>Virtual Panel. Harnessing AI for more efficient clinical trials. March, 26- 2026. <a href="https://www.europeanpharmaceuticalreview.com/webinar/269904/harnessing-ai-for-more-efficient-clinical-trials/?zcs&amp;campaign_source=webinarroundup%20&amp;utm_medium=email&amp;utm_source=dedicated%20eshot&amp;utm_campaign=Harnessing_AI_for_26_march_2026%20&amp;f24_pid=cfa85c0f-fae9-437d-aac4-db2a4d9c4f43">European Pharmaceutical Review.</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=bc1ddf8c2df6" width="1" height="1" alt=""><hr><p><a href="https://medium.com/jose-a-vidal/the-lessons-of-katy-bc1ddf8c2df6">The lessons of Katy</a> was originally published in <a href="https://medium.com/jose-a-vidal">Jose @ Vidal</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>